Allworth Financial’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41K Buy
4,353
+3,244
+293% +$29.1K ﹤0.01% 2658
2026
Q1
$9.03K Buy
1,109
+116
+12% +$1.05K ﹤0.01% 3578
2025
Q4
$6.67K Sell
993
-99
-9% -$746 ﹤0.01% 3538
2025
Q3
$9.47K Buy
1,092
+6
+0.6% +$47 ﹤0.01% 3165
2025
Q2
$6.84K Buy
1,086
+562
+107% +$3.72K ﹤0.01% 3091
2025
Q1
$3.71K Buy
524
+182
+53% +$1.5K ﹤0.01% 2925
2024
Q4
$3.02K Sell
342
-20
-6% -$193 ﹤0.01% 2986
2024
Q3
$4.57K Buy
362
+7
+2% +$90 ﹤0.01% 2608
2024
Q2
$4.92K Buy
355
+13
+4% +$131 ﹤0.01% 2532
2024
Q1
$1.64K Buy
342
+252
+280% +$1.17K ﹤0.01% 2893
2023
Q4
$432 Sell
90
-102
-53% -$624 ﹤0.01% 3165
2023
Q3
$1.39K Sell
192
-25
-12% -$200 ﹤0.01% 2712
2023
Q2
$1.61K Buy
217
+43
+25% +$338 ﹤0.01% 2572
2023
Q1
$1.21K Buy
174
+134
+335% +$1.23K ﹤0.01% 2603
2022
Q4
$411 Sell
40
-55
-58% -$971 ﹤0.01% 2682
2022
Q3
$2K Buy
95
+24
+34% +$1.04K ﹤0.01% 2191
2022
Q2
$4K Buy
71
+29
+69% +$1.5K ﹤0.01% 1827
2022
Q1
$3K Sell
42
-9
-18% -$803 ﹤0.01% 1730
2021
Q4
$7K Buy
51
+31
+155% +$5.33K ﹤0.01% 1498
2021
Q3
$4K Buy
+20
New +$4.41K ﹤0.01% 1570

Other funds holding NVAX

Allworth Financial's NVAX Position: Q2 2026 in Review

Allworth Financial increased its Novavax (NVAX) stake by 293% in Q2 2026, buying an estimated $29.1K and bringing the position to 4,353 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #2658.

Allworth Financial first reported a position in NVAX in Q3 2021 and has held it in 20 quarters since. 266 funds tracked by Wall St. Rank hold NVAX as of Q2 2026.

  • Allworth Financial held 4,353 shares of Novavax worth $41K as of Q2 2026.
  • Allworth Financial bought 3,244 Novavax shares in Q2 2026, an estimated $29.1K.
  • Novavax made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2658 holding.
  • Allworth Financial first reported a position in Novavax in Q3 2021 and has held it in 20 quarters since.
  • 266 funds tracked by Wall St. Rank held Novavax as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.